Oct 15, 2025 06:30AM Keros Therapeutics announces $375 million capital return program

Sep 8, 2025 08:00AM Keros Therapeutics presents KER-065 trial data at bone research meeting

Aug 21, 2025 08:30AM ADAR1 urges Keros board to discuss strategy after meeting requests declined

Aug 20, 2025 09:48AM Keros receives FDA orphan drug designation for KER-065 in DMD treatment

Aug 8, 2025 06:22AM Keros Therapeutics (KROS) PT Lowered to $20 at H.C. Wainwright

Aug 6, 2025 06:13PM Keros Therapeutics (KROS) Tops Q2 EPS by 37c

Aug 6, 2025 04:21PM Keros Therapeutics discontinues cibotercept, focuses on KER-065

Jun 10, 2025 04:16AM BofA Securities Downgrades Keros Therapeutics (KROS) to Neutral

Jun 9, 2025 03:14PM ADAR1 Issues Statement on Keros Therapeutics (KROS) 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 9, 2025 06:55AM Keros Therapeutics (KROS) Return of $375M in Excess Capital to Stockholders

May 29, 2025 06:55AM Keros Therapeutics (KROS) Announces TROPOS Topline Data and Corporate Restructuring

May 27, 2025 01:45PM Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ (KROS) Director Nominees

May 21, 2025 08:06AM ADAR1 Announces ISS Recommends Keros Therapeutics (KROS) Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 8, 2025 02:10PM ADAR1 Capital Management Issues Open Letter to Keros Therapeutics (KROS) Stockholders

May 8, 2025 06:43AM Keros Therapeutics (KROS) PT Lowered to $25 at H.C. Wainwright

May 6, 2025 04:20PM Keros Therapeutics (KROS) Tops Q1 EPS by 481c

Apr 10, 2025 02:08PM Keros Therapeutics (KROS) call put ratio 1 call to 1.1 puts as share price up 20%

Apr 10, 2025 06:19AM Keros Therapeutics (KROS) Announces Review of Strategic Alternatives

Apr 9, 2025 09:34AM Keros Therapeutics (KROS) PT Lowered to $25 at Truist Securities

Mar 31, 2025 06:29AM Keros Therapeutics (KROS) Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065

Mar 5, 2025 05:48AM Increasing unusual put option volume: KROS DB EWC PAYX HSBC NTRA CMA GES NOC CWH

Feb 27, 2025 06:59AM Keros Therapeutics (KROS) PT Lowered to $40 at H.C. Wainwright

Feb 26, 2025 06:37PM Keros Therapeutics (KROS) Tops Q4 EPS by 22c

Jan 21, 2025 08:03AM Keros Therapeutics (KROS) Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Jan 21, 2025 06:30AM Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) to Neutral

Jan 17, 2025 10:40AM Keros Therapeutics (KROS) PT Slashed to $15 at Piper Sandler Following Trial Termination

Jan 16, 2025 08:24AM Keros Therapeutics (KROS) PT Lowered to $23 at Oppenheimer

Jan 16, 2025 06:59AM Keros Therapeutics (KROS) PT Lowered to $41 at Scotiabank

Jan 15, 2025 02:57PM Keros Therapeutics (KROS) January 10 puts and calls active as share price down 15%

Jan 15, 2025 06:30AM Keros Therapeutics (KROS) Announces Additional Update on the Phase 2 TROPOS Trial

Dec 23, 2024 03:11AM Keros Therapeutics (KROS) PT Lowered to $43 at Truist Securities

Dec 16, 2024 07:36AM Keros Therapeutics (KROS) PT Lowered to $63 at Oppenheimer

Dec 13, 2024 07:17AM Keros Therapeutics (KROS) PT Lowered to $47 at H.C. Wainwright

Dec 13, 2024 05:21AM Keros Therapeutics (KROS) PT Lowered to $23 at Jefferies

Dec 12, 2024 09:45AM TD Cowen Downgrades Keros Therapeutics (KROS) to Hold

Dec 12, 2024 09:05AM BTIG Downgrades Keros Therapeutics (KROS) to Neutral

Dec 12, 2024 06:16AM Keros Therapeutics (KROS) Announces Update on the Phase 2 TROPOS Trial

Dec 5, 2024 07:07AM Keros Therapeutics (KROS) PT Raised to $102 at Guggenheim

Dec 3, 2024 10:52AM Keros Therapeutics (KROS) PT Raised to $77 at BofA Securities

Dec 3, 2024 07:00AM Keros Therapeutics (KROS) Announces Global License Agreement with Takeda to Advance Elritercept

Nov 22, 2024 07:07AM Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)

Nov 5, 2024 01:47PM Jefferies Starts Keros Therapeutics (KROS) at Buy

Nov 5, 2024 06:06AM Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS)

Oct 24, 2024 06:45AM Cantor Fitzgerald Starts Keros Therapeutics (KROS) at Overweight

Oct 16, 2024 08:00AM Keros Therapeutics (KROS) Appoints Yung H. Chyung as Chief Medical Officer

Oct 1, 2024 06:28AM Leerink Partners Reiterates Outperform Rating on Keros Therapeutics (KROS)

Sep 23, 2024 02:57AM Guggenheim Starts Keros Therapeutics (KROS) at Buy

Jun 18, 2024 07:57AM Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)

Jun 17, 2024 04:01PM Keros Therapeutics (KROS) Announces Leadership Updates

Jun 17, 2024 06:02AM Keros Therapeutics (KROS) Presents Clinical Data from KER-050 Program